2 results
Approved WMOCompleted
To compare OS in patients with previously untreated Stage IIIc, N3 (unresectable) or Stage IV melanoma receiving dacarbazine plus 10mg/kg ipilimumab (MDX-010) vs. dacarbazine with placebo.
Approved WMOCompleted
To examine features of treatment response on optical coherence tomography in patients who were switched to aflibercept after non-response to previous intravitreal anti-VEGF treatment.